Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: Lansoprazole vs. pantoprazole

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 2, 2003, Pages 235-241

  Frazzoni, M ^a   De Micheli, E ^a   Grisendi, A ^a   Savarino, V ^b  

^a Nuovo Ospedale S Agostino   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; PANTOPRAZOLE; RANITIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RELIABILITY; STOMACH ACID SECRETION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGITIS, PEPTIC; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MANOMETRY; MIDDLE AGED; OMEPRAZOLE; SULFOXIDES;

EID: 0037312635     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01405.x     Document Type: Article

References (40)

1. Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997; 92: 30S-35S.
2. Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
3. Sampliner RE and The Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028-32.
4. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
5. DeVault KR, Castell DO and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-42.
6. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH, Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
7. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
8. Holloway RH, Dent J, Narielvala F, et al. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-54.
9. Barbezat GO, Schlup M, Lubcke R, Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures. Aliment Pharmacol Ther 1999; 13: 1041-5.
10. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35.
11. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalisation of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-6.
12. Richter JE. Extraesophageal presentations of gastroesophageal reflux disease: an overview. Am J Gastroenterol 2000; 95: S1-3.
13. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 700-5.
14. Van Laethem J-L, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-51.
15. Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 2000; 95: 1661-8.
16. Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc 2001; 53: 554-8.
17. DeVault KR. Overview of therapy for the extraesophageal manifestations of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: S39-44.
18. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. Aliment Pharmacol Ther 2002; 16: 35-40.
19. Savarino V, Mela GS, Zentilin P, et al. Variability in individual response to various doses of omeprazole. Dig Dis Sci 1994; 39: 161-8.
20. Blum RA, Hunt RH, Kidd SL, et al. Dose-response relationship of lansoprazole to gastric acid antisecretory effects. Aliment Pharmacol Ther 1998; 12: 321-7.
21. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
22. Parsons ME, Pantoprazole, a new proton-pump inhibitor, has a precise and predictable profile of activity. Eur J Gastroenterol Hepatol 1996; 8(Suppl. 1): S15-20.
23. Savarino V, Mela GS, Zentilin P, et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 1241-7.
24. Stedman CAM, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
25. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
26. Vaira D, Gatta L, Ricci C, Miglioli M. Review article: diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16(Suppl. 1): 16-23.
27. Frazzoni M, Lonardo A, Grisendi A, et al. Are routine duodenal and antral biopsies useful in the management of 'functional' dyspepsia? A diagnostic and therapeutic study. J Clin Gastroenterol 1993; 17: 101-8.
28. Passaretti S, Zaninotto G, Di Martino N, Leo P, Costantini M, Baldi F. Standards for oesophageal manometry. A position statement from the Gruppo Italiano di Studio Motilità Apparato Digerente (GISMAD). Dig Liver Dis 2000; 32: 46-55.
29. Richter JE, Bradley LA, DeMeester TR, et al. Normal 24-hour ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci 1992; 37: 849-56.
30. Katz PO, Anderson C, Khoury R, Castell DO. Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
31. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
32. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther 2002; 16: 881-6.
33. Tutuian R, Katz PO, Bochenek W, Castell DO, Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 829-36.
34. Florent C, Forestier S. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. Eur J Gastroenterol Hepatol 1997; 9: 195-200.
35. Hang JO, Goldwater DR, Thomson ABR, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002; 16: 425-33.
36. Edwards SJ, Lind T, Lundell L, Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1729-36.
37. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
38. Koop H, Kuly S, Flug M, et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 1996; 8: 915-8.
39. Wu JCY, Sung JJY, Chan FKL, et al. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 427-32.
40. Weston AP, Badr AS, Topalovski M, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GORD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95: 387-94.